World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
71
Citations
34255
World Ranking
2266
National Ranking
1097

Overview

Julie E. Ledgerwood is affiliated with the National Institute of Allergy and Infectious Diseases in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a particular focus on infectious diseases, virology, epidemiology, immunology, and public health.

Their main topics of study include:

  • HIV Research and Treatment
  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS drug development and treatment
  • Viral Infections and Outbreaks Research
  • Animal Virus Infections Studies
  • Mosquito-borne diseases and control
  • Monoclonal and Polyclonal Antibodies Research

Ledgerwood has contributed significantly to various scientific publications. Frequent venues for their work are:

  • New England Journal of Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries
  • The Lancet Infectious Diseases
  • Science

Some recent papers include:

  • "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report," 2020, New England Journal of Medicine
  • "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults," 2020, New England Journal of Medicine
  • "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates," 2020, New England Journal of Medicine
  • "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination," 2020, New England Journal of Medicine
  • "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19," 2021, New England Journal of Medicine

Frequent co-authors collaborating with Ledgerwood include:

  • John R. Mascola
  • Adrian B. McDermott
  • Barney S. Graham
  • Emily E. Coates
  • Martin R. Gaudinski

Best Publications

  • Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

    Lindsey R. Baden;Hana M El Sahly;Brandon J Essink;Karen Kotloff

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts

  • A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

    Mulangu S;Dodd Le;Davey Rt;Tshiani Mbaya O

  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

    Evan J. Anderson;Nadine G. Rouphael;Alicia T. Widge;Lisa A. Jackson

  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

    Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica

  • Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

    Robert A. Seder;Lee Jah Chang;Mary E. Enama;Kathryn L. Zephir

  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

    Alicia T. Widge;Nadine G. Rouphael;Lisa A. Jackson;Evan J. Anderson

  • Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

    Nicole Doria-Rose;Mehul S. Suthar;Mat Makowski;Sarah O’Connell

  • Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.

    Hana M El Sahly;Lindsey R Baden;Brandon Essink;Susanne Doblecki-Lewis

  • Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.

    Pegu, Amarendra, O’Connell, Sarah E.;Stephen D. Schmidt;O’Dell, Sijy, Talana, Chloe A.

  • Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

    Katharine J Bar;Michael C Sneller;Linda J Harrison;J Shawn Justement

  • Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

    Rebecca M. Lynch;Eli Boritz;Emily E. Coates;Adam DeZure

  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

    Lawrence Corey;Peter B Gilbert;Michal Juraska;David C Montefiori

  • A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

    Jason A. Regules;John H. Beigel;Kristopher M. Paolino;Jocelyn Voell

  • Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

    Joan O. Ngwuta;Man Chen;Kayvon Modjarrad;Kayvon Modjarrad;M. Gordon Joyce

  • Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

    Davide Corti;John Misasi;Sabue Mulangu;Daphne A. Stanley

  • Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.

    Andrew S Ishizuka;Kirsten E Lyke;Adam DeZure;Andrea A Berry

  • Chimpanzee Adenovirus Vector Ebola Vaccine

    Julie E. Ledgerwood;Adam D. DeZure;Daphne A. Stanley;Emily E. Coates

  • Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

    M. Gordon Joyce;Adam K. Wheatley;Paul V. Thomas;Gwo-Yu Chuang

  • A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

    Katie Ewer;Tommy Rampling;Navin Venkatraman;Georgina Bowyer

  • Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

    Rebecca S. Rudicell;Young Do Kwon;Sung-Youl Ko;Amarendra Pegu

Frequent Co-Authors

Barney S. Graham
Barney S. Graham Morehouse School of Medicine
John R. Mascola
John R. Mascola ModeX Therapeutics
Robert T. Bailer
Robert T. Bailer National Institute of Allergy and Infectious Diseases
Richard A. Koup
Richard A. Koup National Institute of Allergy and Infectious Diseases
Adrian B. McDermott
Adrian B. McDermott National Institute of Allergy and Infectious Diseases
Mario Roederer
Mario Roederer National Institute of Allergy and Infectious Diseases
Martha C. Nason
Martha C. Nason National Institutes of Health
Gary J. Nabel
Gary J. Nabel ModeX Therapeutics
Theodore C. Pierson
Theodore C. Pierson National Institute of Allergy and Infectious Diseases
Nancy J. Sullivan
Nancy J. Sullivan National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in immunology, pursuing related nursing degrees online can open diverse career pathways in healthcare. Many aspiring nurses start with foundational programs like the easiest accelerated nursing programs to get into, allowing them to fast-track their education and begin clinical work sooner.

For non-nurses seeking to enter the nursing field, online options such as online RN programs for non nurses in Florida provide flexibility and accessibility. These programs cater to career changers and help build essential clinical expertise, which complements immunology knowledge in patient care settings.

Those who have already earned a Family Nurse Practitioner (FNP) credential can enhance their scope by enrolling in an fnp to acute care np bridge program. This pathway is ideal for professionals aiming to specialize in acute care environments, where immunological knowledge is critical for managing complex cases.

Additionally, accelerated FNP programs offer a streamlined route for nurses looking to advance their careers and integrate immunology principles into advanced practice roles. These programs combine rigorous clinical training with cutting-edge research, preparing graduates for impactful careers in immunology-related health fields.

Best Scientists Citing Julie E. Ledgerwood

Trending Scientists

Recently Published Articles